BiotechTube

BL-8040 + horse anti-thymocyte globulin (hATG) + Methylprednisolone + Cyclosporine

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Aplastic Anemia

Conditions

Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome

Trial Timeline

Oct 1, 2015 → Nov 1, 2020

NCT ID
NCT02462252

About BL-8040 + horse anti-thymocyte globulin (hATG) + Methylprednisolone + Cyclosporine

BL-8040 + horse anti-thymocyte globulin (hATG) + Methylprednisolone + Cyclosporine is a phase 2 stage product being developed by BioLineRx for Aplastic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02462252. Target conditions include Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02462252Phase 2Completed

Competing Products

20 competing products in Aplastic Anemia

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
AlefaceptAstellas PharmaPhase 1
33
RomiplostimKyowa KirinPhase 2/3
65
Lenvatinib 24 mgEisaiPhase 2
52
RomiplostimKyowa KirinPhase 2/3
65
RomiplostimKyowa KirinPhase 2/3
65
AMG531Kyowa KirinPhase 2
52
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
52
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine + PlaceboJiangsu Hengrui MedicinePhase 3
77
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporinJiangsu Hengrui MedicinePhase 2
52
Hetrombopag Olamine Tablet；Ciclosporin Soft CapsuleJiangsu Hengrui MedicinePhase 1
33
Hetrombopag Olamine TabletJiangsu Hengrui MedicinePhase 1
33
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1/2
41
Hetrombopag Olamine+Standard Therapy + Placebo+Standard TherapyJiangsu Hengrui MedicinePhase 3
77
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
PosaconazoleMerckPhase 2
52
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension CohortNovartisPhase 1/2
41

Other Products from BioLineRx

BL-8040 1.25 mg/kg + G-CSF + Placebo +G-CSFPhase 3
69
CYP-1020 + RisperidonePhase 2/3
57
BL-8040Phase 2
44
BL - 1020 + BL - 1020 + Placebo + RisperidonePhase 2
44
BL-1020 + BL 1020 High DosePhase 2
44